The Group’s strategy and business model is explained within the Strategic Report on page 08 of the Group’s Annual Report and Financial Statements 2024 and is summarised below.
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and precision medicine. ANGLE is commercialising the Parsortix system, for the isolation and harvest of intact, living cancer cells from a simple blood sample, together with associated tests for the analysis of these cells.
ANGLE’s Parsortix system is a platform technology using a proprietary microfluidic device that captures cells based on a combination of their size and compressibility. The system has been exemplified in 24 cancer types and is the subject of granted patents in multiple jurisdictions.
ANGLE has developed a range of tests for the analysis of harvested cancer cells. These tests assess the status of a range of clinically actionable biomarkers and have the potential to deliver profound improvements in health economic outcomes and in the treatment and management of many types of cancer.
ANGLE’s vision “Improving outcomes for cancer patients through liquid biopsy blood tests“ is being achieved by securing widespread adoption of the Parsortix system through providing CTCs as the “best sample” for repeatable real-time cancer assessment. The Parsortix system, coupled with ANGLE’s state-of-the-art molecular and imaging assays, will enable highly sensitive multiomic analysis of CTCs.
To drive commercialisation, ANGLE has established a services business and a product business:
- Services business area
The primary commercialisation route for the Parsortix system, assays and workflows, is through partnership with large pharma, where liquid biopsy assays can support drug discovery and development with a view to adoption as a companion diagnostic to support optimal use of their cancer drugs. ANGLE has developed bespoke imaging assays to meet our customers’ needs and can offer state-of-the art molecular assays which leverage the rapid technological advancements in sequencing and AI. This is enabling the analysis of CTCs with increasing throughput and sensitivity. - Product business area
ANGLE’s sales of the Parsortix system, assays and consumables to independent cancer centres and research institutes continues to drive breakthrough research and first-in-class discoveries which may flow through into commercial drug development. During the reporting period this led to the publication of numerous posters and 12 peer-reviewed journal articles by independent study centres.Due to the rising cost of drug discovery and development, pharmaceutical companies continue to reduce in-house research and are increasingly collaborating with, and relying on, research undertaken by academia to identify new drug targets and novel therapeutics. This means that academic and translational research is now the driving force behind the pharmaceutical and biotech industries, supporting drug discovery and development. Examples of how research published in the period translates into tangible value includes the identification of novel drug targets, new insight into the metastatic process and novel drugs which could reduce the spread of cancer, and demonstrating how the Parsortix system can be used to select the most appropriate patients for drug trials.
Corporate governance
AIM rule 50